Shares of Devonian Health Group Inc. (CVE:GSD – Get Free Report) dropped 23.5% during mid-day trading on Saturday . The stock traded as low as C$0.09 and last traded at C$0.13. Approximately 119,000 shares changed hands during trading, an increase of 588% from the average daily volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Stock Down 23.5%
The business has a 50-day moving average of C$0.16 and a 200-day moving average of C$0.17. The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07. The stock has a market capitalization of C$19.27 million, a price-to-earnings ratio of -4.64 and a beta of 0.67.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Further Reading
- Five stocks we like better than Devonian Health Group
- What Are Growth Stocks and Investing in Them
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- 10 Best Airline Stocks to Buy
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
